Topics

This morning, we reported strong third-quarter 2019 financial results, highlighted by 9% operational revenue growth in our innovative biopharmaceuticals business.

07:07 EDT 29 Oct 2019 | Pfizer

This morning, we reported strong third-quarter 2019 financial results, highlighted by 9% operational revenue growth in our innovative biopharmaceuticals business.

Original Article: This morning, we reported strong third-quarter 2019 financial results, highlighted by 9% operational revenue growth in our innovative biopharmaceuticals business.

NEXT ARTICLE

More From BioPortfolio on "This morning, we reported strong third-quarter 2019 financial results, highlighted by 9% operational revenue growth in our innovative biopharmaceuticals business."

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...